Ishaan Aditya Sharma

Strategizing Customer Value Proposition Of Credit Card

Worked with Cashback Credit Card Product Managers from HSBC Asia Pacific regions and built the framework in SAS-SQL to arrive at expected cashback for the new CVP launch

• Strategized corrective actions in CVP and simulated different CVPs to align with country's cashback budget.
• New ROTE is expected to be >20%, a significant increase over the current CVP's

Breakeven By Channel CPA

• Built 5 year PnL of new Credit Card acquisition at channel level for HSBC India Portfolio to determine breakeven mob.
• Strategized solution/acquisition strategy to turn ROTE negative credit card products in India portfolio to achieve at least 12% ROTE in next 5 years

Pricing and Customer Targeting Analytics

• Updated Customer Targeting strategy during relaunch of Australia PL to expand acquisition base by 15%
• Strategized Test and Control Pricing for Taiwan X-sell Personal Loans based on credit card risk segmentation. New Pricing test was implemented from Jan'24

Market Sizing Analysis

Used Rx claims from Immunology, AD market to generate KPIs like claim volume, quantity, units dispensed for all the indications at Practitioner Level for a fortune 500 client

• Results support client's multiple practitioner and territory-specific analysis like Sales Planning, Targeting, Performance measurement
• Overall project success resulted in end-client getting awarded and brought in a multiyear million dollar contract for our organization

Physician Targeting Projects

• Built Promotional Triggers for multiple clients, which were used by sales rep to target physicians at the right time to enhance sales of client's products. For a client, over 1 year time period, the triggers boosted product sales of the launch phase by 19% over the client's expected target

Predicting Patient Outcomes Using Medical History

Created statistical model to predict the probability of incidence of Patient outcomes using claims data. Validated disease significance for future outcomes by comparing incidence rates with a random patient population

• Helped client's clinical team to prove that outcomes are linked to the disease and not the under-trial clinical drug

Economic Impact Analysis Of Disease Burden

Determined impact and year-wise trend of disease burden in NASH Patients. Adjusted cost and resource utilization based on patient demographics

• Results complimented the Fast-Track Drug approval application to US-FDA for client's under-trial clinical drug